Blood-Derived Products for Chronic Non-Healing Wounds — NCD 217 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 217, the National Coverage Determination governing Medicare coverage of blood-derived products for chronic non-healing wounds, effective March 7, 2026. Here's what billing teams need to know before claims hit the queue.

This policy update confirms CMS's coverage framework for autologous platelet-rich plasma (PRP) and platelet-derived growth factor (PDGF) products used in wound care. The CMS blood-derived products coverage policy draws a hard line between what Medicare pays for nationally and what gets kicked to your local Medicare Administrative Contractor. The policy does not list specific CPT or HCPCS codes — more on what that means for your team below.

Quick-Reference Table

CMS Blood-Derived Products Coverage Criteria and Medical Necessity Requirements 2026

The NCD 217 Medicare coverage policy splits into two categories: what CMS covers nationally and what your MAC decides locally. That split is where most billing problems start.

For national coverage, CMS covers autologous PRP for chronic non-healing diabetic wounds. The coverage window is 20 weeks. The device used to prepare the PRP must have FDA clearance for managing exuding cutaneous wounds — such as diabetic ulcers — specifically under that cleared indication. If your device doesn't meet that FDA clearance criterion, you don't have a covered claim, regardless of clinical outcome.

Medical necessity documentation needs to show that the wound is chronic, not acute. CMS defines chronic here as a wound that has failed to progress through normal healing stages within a sufficient time period. The policy language points to wounds persisting 30 days or longer that fail to properly complete the healing process. That 30-day threshold needs to be in your documentation before you bill a single unit.

The autologous requirement matters. PRP must come from the patient's own blood — centrifuged, prepared, and applied in a clinical setting. Homologous PRP, derived from multiple donors, does not have a nationally covered indication under this policy. If your physician is using donor-derived product, the coverage picture changes entirely, and you need to assess your MAC's local coverage determination before billing.

Prior authorization is not explicitly required under the national coverage indications in this NCD. But 20 weeks is a hard boundary for national coverage. After week 20, coverage determination shifts to your MAC, and some MACs do require prior authorization for continued wound care services. Check your MAC's LCD before week 16 — not week 20.

Reimbursement under this coverage policy depends on the device clearance, the wound type, and the duration of treatment. None of those are details you can reconstruct after a claim denial. Get them documented upfront.

CMS Blood-Derived Products Exclusions and Non-Covered Indications

Three categories are nationally non-covered under NCD 217. These are not gray areas. CMS has drawn these lines at the national level, meaning no MAC can override them with a local coverage determination.

Autologous PDGF for chronic, non-healing cutaneous wounds. PDGF products — previously marketed as home-use treatments — are not covered. The historical context matters here: PDGF doesn't contain cells, and CMS has consistently drawn a distinction between cell-containing PRP and cell-free PDGF. That distinction now has policy teeth.

Becaplermin for chronic, non-healing subcutaneous wounds. Becaplermin is a non-autologous growth factor. CMS's non-covered designation here is specific to subcutaneous wounds. If your team has been billing becaplermin for deep wound treatment under Medicare, those claims are denied at the national level.

Autologous PRP for acute surgical wounds or dehiscent wounds when applied directly to a closed incision. This is a common clinical use case, and it's non-covered. If the wound is acute — meaning it's expected to heal normally — or if the PRP is being applied to a closed surgical incision, you don't have a covered indication. Document the wound classification carefully. "Dehiscent" wounds can be confused with chronic wounds, but the policy treats them separately.

The real issue here is documentation specificity. A vague wound description in the chart doesn't just create a medical necessity problem — it creates a coverage classification problem. Your billing team can't fix a claim that the clinical documentation won't support.

Coverage Indications at a Glance

CMS Blood-Derived Products Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 means this version of the policy is the governing document now. Here's what to do before your next wound care claim goes out.

CPT, HCPCS, and ICD-10 Codes for Blood-Derived Products Under NCD 217

The policy data for NCD 217 (v6) does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for CMS national coverage determinations — code-level specificity often lives in the claims processing transmittals rather than the NCD itself.

Three transmittals are referenced in the policy: TN 10981, TN 11119, and TN 11171. These Medicare Claims Processing transmittals contain the actual code-level billing instructions for blood-derived products billing under this NCD. Pull all three before updating your charge capture.

Where to Find the Codes

Do not guess at codes based on clinical descriptions. The transmittals will tell you the exact HCPCS codes to report. Using the wrong code on a blood-derived products claim under Medicare is a faster path to a claim denial than almost any documentation error.

Your MAC's local coverage determination will list the diagnosis codes required to support medical necessity for non-diabetic wound PRP or extended treatment. Those ICD-10-CM codes are not in this NCD — they live in the LCD. Pull both documents and reconcile them before billing.